Amgen's G-CSF
Executive Summary
Amgen's G-CSF: Results of early clinical study published in December's British Journal of Cancer show all 12 advanced lung cancer patients receiving the recombinant growth factor having "a significant increase" in white blood cell levels, Amgen reports. Patients, who were undergoing treatment with a combination of anticancer drugs, received up to six cycles of chemotherapy with G-CSF on alternating cycles of therapy.